www.onclive.com
Open in
urlscan Pro
76.76.21.142
Public Scan
Submitted URL: http://www.onclive.com/
Effective URL: https://www.onclive.com/
Submission: On February 05 via api from US — Scanned from DE
Effective URL: https://www.onclive.com/
Submission: On February 05 via api from US — Scanned from DE
Form analysis
1 forms found in the DOMGET /search
<form method="GET" action="/search">
<div class="relative">
<div class="text-gray-600 absolute ml-3 inset-0 m-auto lg:w-4 lg:h-4 md:w-6 md:h-6"><button aria-label="submit" type="submit" class="absolute block inset-0"><svg xmlns="http://www.w3.org/2000/svg"
class="text-gray-600 stroke-current icon icon-tabler icon-tabler-search" viewBox="0 0 24 24" stroke-width="2" stroke="currentColor" fill="none" stroke-linecap="round" stroke-linejoin="round">
<path stroke="none" d="M0 0h24v24H0z"></path>
<circle cx="10" cy="10" r="7"></circle>
<line x1="21" y1="21" x2="15" y2="15"></line>
</svg></button></div><input type="text" required="" name="searchTerm" class="block border border-gray-200 focus:outline-none focus:border-indigo-700 lg:w-48 xl:w-64 rounded text-sm text-gray-800 pl-8 py-2" placeholder="Search">
</div>
</form>
Text Content
News OncClubAll Oncology NewsPipeline Report Media InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk Conferences Conference CoverageConference Listing Events Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars Partners Publications Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications CME/CE Resources Interactive ToolsLearning ModulesPresentationsSponsored Biomarker Consortium Subscribe Print SubscriptioneNewsletter Choose Specialty Biosimilars Brain Cancer Breast CancerBreast Cancer CAR T-cell Therapy COVID-19 Disparities in Cancer Care Gastrointestinal CancerGastrointestinal Cancer Genitourinary CancersGenitourinary CancersGenitourinary Cancers Global Oncology Gynecologic OncologyGynecologic Oncology Head & Neck Cancers Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Oncology Nursing News Pediatric Oncology Precision Medicine in Oncology®Precision Medicine in Oncology® Sarcomas/TGCT Supportive Care Spotlight - * In-person and virtual events just for HCPs Choose Specialty Biosimilars Brain Cancer Breast CancerBreast Cancer CAR T-cell Therapy COVID-19 Disparities in Cancer Care Gastrointestinal CancerGastrointestinal Cancer Genitourinary CancersGenitourinary CancersGenitourinary Cancers Global Oncology Gynecologic OncologyGynecologic Oncology Head & Neck Cancers Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology Lung Cancer Melanoma & Skin Cancer Oncology Business Management Oncology Nursing News Pediatric Oncology Precision Medicine in Oncology®Precision Medicine in Oncology® Sarcomas/TGCT Supportive Care * * Spotlight * News * Media * Conferences * Events * Partners * Publications * CME/CE * Resources * Biomarker Consortium * Subscribe Advertisement -------------------------------------------------------------------------------- LATEST NEWS World Cancer Day Highlights Ways to Address Gaps in Care for Black Patients With Breast Cancer By Ryan Scott February 4th 2024 World Cancer Day is held every year on February 4th, prompting individuals across the globe to expand awareness within cancer care. Linvoseltamab Continues to Elicit Durable Efficacy in High-Risk Relapsed/Refractory Multiple Myeloma By Ryan Scott February 3rd 2024 Pirtobrutinib Continues to Show Safety, Activity in Covalent BTK Inhibitor–Pretreated R/R MCL By Courtney Flaherty February 3rd 2024 EMA Validates MAA for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer By Kristi Rosa February 2nd 2024 FDA Grants Orphan Drug Designation to Efineptakin Alfa for Pancreatic Cancer By Kristi Rosa February 2nd 2024 Latest Videos Unmet Needs in the Allogeneic Hematopoietic Stem Cell Transplant Population Dr Mikhael on Unmet Needs in Cancer Care for Patients With Multiple Myeloma Clinical Case 4: Radiation Therapy Sequencing With CAR T-Cell Therapy for LBCL Dr Halmos on Treatment Strategies For EGFR-Mutant NSCLC Dr Siegel on the Importance of Closing the Gaps in Cancer Care Dr Curran on Developing Strategies for Stage III NSCLC Management Dr Simon on the Utility of Novel Treatments in Diverse Patient Populations With Cancer Dr Levy on Unanswered Questions Regarding the Mechanism of Action of ADCs in NSCLC Dr Leal on the Development of DLL3-Targeted Agents in SCLC Dr Pellini on the Development of Increasingly Sensitive ctDNA Assays in NSCLC Dr Rodriguez on the Use of HER2-Directed Therapies in NSCLC Dr George on the CheckMate 8Y8 Trial of Nivolumab With/Without Ipilimumab in Untreated RCC Dr Castillo on Acalabrutinib Plus Rituximab in Patients With Anti-MAG IgM Peripheral Neuropathy Patient Case Studies of GvHD Treatment Resistance with Covalent BTKis: Translating Data into Clinical Practice Expert Insights into Navigating Cardiovascular Risks with BTKi Therapy Dr Yu discusses the ARCAD Nomogram in a Real-World CRC Population Dr Bryant on the Background For Investigating Germline DNA Repair Mutations in PDAC Dr Yaeger on the Background of the CodeBreaK 101 Trial in mCRC Biomarker Consortium Videos Key Elements of an NGS Testing Report Interpreting the Results of an NGS Testing Report How is Biomarker Testing Performed and Utilized? Addressing Concerns Regarding Biomarker Testing Tissue and Plasma-Based Mechanisms of Resistance to First-Line Osimertinib in EGFR-Mutant NSCLC: A Multi-Institutional Cohort Predictive Biomarkers for Treatment With Amivantamab Plus Lazertinib Among EGFR-Mutated NSCLC in the Post-Osimertinib Setting: Analysis of Tissue IHC and ctDNA NGS Real-World Testing and Treatment Patterns Among Patients With Stage IV NSCLC: A Retrospective Observational Study Contemporary Biomarker Testing Rates in Both Early and Advanced NSCLC: Results From the MYLUNG Pragmatic Study What is NGS Testing? What is DNA and RNA Testing in Biomarker Testing? Why Are You Choosing a Certain Testing Platform in Biomarker Testing? How Do You Explain Adjuvant Therapy in NSCLC? When Should Patients With NSCLC be Referred to Thoracic Surgeons in Specialized Centers of Care? What are the Benefits and Side Effects of TKIs? What is a Biomarker in the Context of Tumors? What is a Gene Mutation and a Gene Fusion? What is a Chromosomal Rearrangement? How Do You Explain Neoadjuvant Therapy in NSCLC? What are Challenges Around Access to Testing? What are the Benefits and Side Effects of Immunotherapy? Latest CME Events & Activities In-Person EventCME,CNE 21st Annual Winter Lung Cancer Conference® February 2-4, 2024 Register Now! Archived WebcastCME Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes View More Archived WebcastCME Keeping Pace with Rapid Advancements in Multiple Myeloma Care View More Oncology Town Hall®CME Oncology Town Hall™: Primary Investigators Present Key Abstracts in the Management of CLL View More Community Practice Connections™CME Maximizing Our Clinical Practices in Hodgkin Lymphoma: Integration of Recent Data Sets in Real World Settings View More Community Practice Connections™CME Community Practice Connections™: Matching the Tumor With Patient-Specific Goals to Inform Frontline Selection and Sequencing in Chronic Lymphocytic Leukemia View More Community Practice Connections™CME,CPE State-of-the-Art CMV Care: Experts’ Perspectives on Primary/Secondary Prevention and Management of Refractory/Resistant Infections View More Clinical Vignette Series™CME,CNE Clinical Vignettes: Inaugural International Congress on Pediatric Oncology View More ALL ONCOLOGY NEWS A-Plus Machine Learning Approach Displays Accurate Cancer Detection With Smaller Sample Amounts By Kyle Doherty February 2nd 2024 Investigators have developed a machine learning algorithm that could eventually facilitate earlier cancer detection via smaller blood draws. EMA Accepts Marketing Authorization Application for Linvoseltamab in R/R Multiple Myeloma By Caroline Seymour February 2nd 2024 The EMA has accepted for review an MAA seeking the approval of linvoseltamab for use in select patients with relapsed/refractory multiple myeloma. Lenvatinib/Pembrolizumab Maintained Beneficial Outcomes When Evaluated by Tumor Size in RCC By Ryan Scott February 2nd 2024 Lenvatinib/pembrolizumab demonstrated efficacy irrespective of tumor burden in advanced renal cell carcinoma in the overall patient population of the phase 3 CLEAR study. Elevated Blood Levels of NT-proBNP in Cancer Survivors Link With Higher Risks of Death By Dana-Farber Cancer Institute February 2nd 2024 Cancer survivors with elevated levels of NT-proBNP have a higher risk of death, according to an analysis conducted by Dana-Farber Cancer Institute. Lonial Spotlights CAR T-Cell and Off-the-Shelf Treatments in Multiple Myeloma By Megan Hollasch February 2nd 2024 Sagar Lonial, MD, FACP, details how CAR T-cell therapies and off-the-shelf treatments are improving outcomes for patients with multiple myeloma. Japanese Approval Sought for Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer By Kristi Rosa February 2nd 2024 A sNDA seeking approval of enfortumab vedotin plus pembrolizumab for first-line use in patients with urothelial cancer has been submitted to Japan’s MHLW. SCO-101 Plus FOLFIRI Shows Signs of Efficacy in Metastatic Colorectal Cancer By Kristi Rosa February 1st 2024 The combination of SCO-101 and FOLFIRI resulted in tumor reduction and increased progression-free survival in patients with metastatic colorectal cancer. Camidge and Okuyama Sasaki Highlight How Safety Net Hospitals Widen the Scope of Cancer Care By OncLive Staff February 1st 2024 Drs Camidge and Okuyama Sasaki discuss the goals of safety net hospitals and the dynamics of helping low-income patients access cancer treatments. Physician Expectations Regarding the FDA Approval Process May Differ From Reality By Megan Hollasch February 1st 2024 Sanket Dhruva, MD, MHS, details examining the perspectives of physicians regarding the FDA approval process for drugs and high-risk medical devices. FDA Grants Priority Review to Afami-Cel BLA in Advanced Synovial Sarcoma By Ryan Scott February 1st 2024 The FDA has accepted for priority review the BLA seeking the approval of afamitresgene autoleucel for the treatment of advanced synovial sarcoma. FDA Grants Fast Track Designation to BST02 for Liver Cancer By Caroline Seymour February 1st 2024 The FDA has granted a fast track designation to the T-cell therapy BST02 for the treatment of patients with all forms of liver cancer. SABCS 2023 Findings Build on Positive Momentum in HER2+ Breast Cancer By Kyle Doherty February 1st 2024 Expert oncologists in the field of breast cancer review data in HER2-positive early-stage and metastatic breast cancer. Updated CheckMate 649 Data Reinforce Nivolumab Plus Chemo as Frontline SOC in Advanced Gastric Cancers By Courtney Flaherty February 1st 2024 Kohei Shitara, MD, discusses 4-year survival data of chemotherapy plus nivolumab in advanced gastric/GEJ cancer or esophageal adenocarcinoma. Investigators Set to Explore Selinexor Monotherapy or Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis By Ashling Wahner January 31st 2024 Selinexor is under investigation as monotherapy and in combination with the JAK inhibitor ruxolitinib in patients with JAK inhibitor–naive myelofibrosis. Ziftomenib Combos Show Early Safety, Activity in NPM1-Mutant and KMT2A-Rearranged AML By Kristi Rosa January 31st 2024 An acceptable safety profile and early evidence of clinical activity was observed with ziftomenib plus standard regimens in select patients with AML. Garmezy Highlights Ongoing and Future Research Directions Across RCC Subtypes By Courtney Flaherty January 31st 2024 Benjamin Garmezy, MD, provides an overview of recent data on immuno-oncology/TKI combination data in variant renal cell carcinoma. KRAS G12C–Targeted Therapies May Move Earlier in the mCRC Treatment Sequence By Ashling Wahner January 31st 2024 Rona Yaeger, MD, discusses a study of second-line sotorasib plus panitumumab in patients with KRAS G12C–mutated colorectal cancer. sBLA Submitted to FDA for Subcutaneous Daratumumab Plus VRd in Transplant-Eligible Multiple Myeloma By Kyle Doherty January 31st 2024 A sBLA seeking the approval of D-VRd for transplant-eligible patients with newly diagnosed multiple myeloma was submitted to the FDA. Actionable Molecular Findings: Increasingly Clinically Relevant but Also Increasingly Complex By Maurie Markman, MD January 31st 2024 Maurie Markman, MD, discusses the need for a decision support strategy to assist oncologists in treatment selection for patients with actionable mutations. FDA Grants Priority Review to Adjuvant Alectinib for Early-Stage ALK+ NSCLC By Kristi Rosa January 31st 2024 The FDA granted priority review to a sNDA seeking the approval of alectinib as adjuvant treatment after surgery for early-stage ALK-positive NSCLC. ELAINE-3 Trial Sets Out to Confirm Clinical Benefit of Lasofoxifene/Abemaciclib in ESR1-Mutant, ER+ Breast Cancer By Courtney Flaherty January 30th 2024 Seth A. Wander, MD, PhD, discusses key findings with lasofoxifene from ELAINE-1 and ELAINE-2 that supported the initiation of the ELAINE-3 trial. FDA Grants Priority Review to Expand Liso-Cel Indications in R/R Follicular Lymphoma and MCL By Kristi Rosa January 30th 2024 Liso-cel sBLAs for indications in relapsed/refractory FL and MCL after exposure to a BTK inhibitor have received priority review from the FDA. Hobbs Highlights Key Research in Hematologic Malignancies at the 2023 ASH Annual Meeting By Courtney Flaherty January 30th 2024 Gabriela Hobbs, MD, discusses the significance of key research across myeloproliferative neoplasms from the 2023 ASH Annual Meeting. EMA Validates Application for First-Line Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer By Courtney Flaherty January 30th 2024 The type II variation application for enfortumab vedotin plus pembrolizumab in untreated metastatic urothelial cancer has been validated by the EMA. Targeted Agents and Combination Therapies May Open Doors in MDS Management By Ashling Wahner January 30th 2024 Talha Badar, MBBS, MD, discusses the FDA approval of ivosidenib for patients with myelodysplastic syndrome and the future management of this disease. See All News > Advertisement LATEST CONFERENCE COVERAGE Dr Halmos on Treatment Strategies For EGFR-Mutant NSCLC Dr Curran on Developing Strategies for Stage III NSCLC Management Dr Levy on Unanswered Questions Regarding the Mechanism of Action of ADCs in NSCLC Dr Leal on the Development of DLL3-Targeted Agents in SCLC View More Latest Conference Coverage Advertisement Recent Content World Cancer Day Highlights Ways to Address Gaps in Care for Black Patients With Breast Cancer Linvoseltamab Continues to Elicit Durable Efficacy in High-Risk Relapsed/Refractory Multiple Myeloma Pirtobrutinib Continues to Show Safety, Activity in Covalent BTK Inhibitor–Pretreated R/R MCL EMA Validates MAA for Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer View More Recent Content Advertisement x Advertise About OncLive Editorial Board CancerNetwork.com CGTlive.com CureToday.com OncNursingNews.com TargetedOnc.com Contact Us Privacy Terms & Conditions Do Not Sell My Information Contact Info 2 Commerce Drive Cranbury, NJ 08512 609-716-7777 © 2024 MJH Life Sciences All rights reserved. Home About Us News Contact